【投后新闻】山东亨利完成7600万美元A轮融资,费城建立全球总部,前GSK副总裁加盟
2018-01-09 00:00:00

      


       过去5年,于中国济南创立的KBP Biosciences(下称KBP)在中国的新药渠道得到了稳步的发展。近日,KBP公布了一条令人欣喜的好消息—公司计划于费城建立全球总部并且宣布完成了7600万美元的A轮融资,而这笔钱也将被新任的美国CEO用于公司在美国市场的开拓。



            


         本轮融资由尚珹资本(Advantech Capital)和国投创新(SDIC Venture Capital)共同领投,仙瞳资本(SangelCapital)和平安创新投资基金(Ping An Ventures)、BayCity Capital GF XINDE Life Science Investment Fund倚锋创投(Efung Capital)、国科嘉和(CASH Capital)、同创伟业(Cowin Capital Group)、Korea InvestmentPartners、以及才金资本(Elite Capital)一起参与了投资。

 

        同时,KBP Biosciences任命前GSK(葛兰素史克)副总裁Brian McVeigh先生为其新的首席执行官。


          

                                                                 (图为Brian McVeigh


      山东亨利医药科技有限责任公司(KBP BioSciences Co., Ltd.)是一家致力于国际化创新药物研发的公司。亨利医药借鉴国际最前沿的创新药物研究开发理念,结合公司自身特点,以临床未满足的需求为目标,专注于包括心脑血管疾病、多重耐药细菌感染以及炎症和自身免疫性疾病为主的三个治疗领域。公司建立了独特的发现、开发一体化技术平台,充分支持全球首创新药的研究和开发。亨利医药所有新药均通过FDA和CFDA申报,并且率先在美国开展临床。迄今已经有3个药物获得FDA和CFDA的IND审批,并在美国进入临床试验。亨利医药美国公司有资深的临床以及市场管理团队,负责公司新药在美国的临床开发以及后期的市场运作。


 

下为原文:

China’s KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly

Over the past 5 years KBP Biosciences has been steadily growing up its pipeline of new drugs from its base in China. But this morning the biotech company is unveiling a dramatic change of scene, with plans to set up a global headquarters in Philadelphia while taking the wraps off a $76 million venture round that will give its new American CEO the cash to make a splash at the FDA.


The new CEO is Brian McVeigh, a 25-year veteran of GlaxoSmithKline, where until very recently he headed up the global business development team inside the pharma giant’s extensive Philly hub. McVeigh tells me he plans to put that BD experience to work for KBP.


“This is the first company I’ve ever come across which has a truly significant pipeline but is also just closing the Series A,” McVeigh tells me.


That’s because Zhen Hua Huang in Jinan, China built the novel drug platform for this company, spinning it out of a generics company he had built and sold. Now KBP has three clinical programs and a set of preclinical efforts with a staff of about 50 currently. McVeigh is building the C-suite in the US, and he’ll be the point person for leading development efforts for the US market.


The immediate focus is on a Phase IIb-ready cardio drug dubbed KBP-5074.


The drugs are coming from China, and so is most — though not all — of the new money.


Advantech Capital and China’s state-backed SDIC Venture Capital led the round, with contributions from Sangel Capital, Ping An Ventures, Bay City Capital GF XINDE Life Science Investment Fund, Efung Capital, CASH Capital, Cowin Capital Group, Korea Investment Partners and Elite Capital.


It’s an unusual move in many ways. China has seen a host of startups come on strong, often pursuing a strategy of in-licensing late-stage or marketed drugs from the US. This biotech is building drugs from the ground up, with a worldwide strategy and enough cash to see if it can work.


“I look at China as it’s finally here; there’s true innovation coming from China,” says the CEO. And recent changes in China’s regulatory approach — speeding up reviews and allowing companies like KBP to use US data to gain Chinese approvals — positions the country to leapfrog the US drug market in the future.


McVeigh wanted in on the ground floor of that trend.



首 页
关于我们
仙瞳新闻
金融资讯
委托投资
人才招聘
联系我们
孵化项目
公司简介
公司理念
关注领域
 
行业动态
行业信息
投资优势
委托投资
人才理念
招聘职位
深圳仙瞳资本管理有限公司
地址:深圳市南山区深圳湾创业投资大厦2401/2402
电话0755-26069007
传真:0755-26491800
网址:www.sangelvc.com

Copyright © 2008-2016 | All Rights Reserved | 深圳仙瞳资本管理有限公司官网  Shenzhen Sangel Venture Capital Co.,Ltd. | 粤ICP备15012769号